SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
12. Juli 2023 07:00 ET
|
SparingVision
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...